Cas No.: | 1242422-09-8 |
Chemical Name: | 4-(N-methyl-N-(4-(trifluoromethyl)phenyl)sulfamoyl)-N-(4-(pyridin-2-yl)thiazol-2-yl)benzamide |
Synonyms: | SSTC 3;SSTC-3 |
SMILES: | C(NC1=NC(C2=NC=CC=C2)=CS1)(=O)C1=CC=C(S(N(C)C2=CC=C(C(F)(F)F)C=C2)(=O)=O)C=C1 |
Formula: | C23H17F3N4O3S2 |
M.Wt: | 518.529 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | SSTC3 is a novel small-molecule CK1α activator with EC50 of 30 nM (WNT-driven reporter gene assay), Kd of 32 nM; has better pharmacokinetic properties than pyrvinium, attenuates the growth of such Apc mutant organoids with EC50 of 2.9 uM; decreases the viability of the WNT-dependent cell lines (EC50 = 132, 63, and 123 nM for HT29, SW403, and HCT116 cells, respectively), inhibits the growth of CRC xenografts in mice; also attenuates the growth of patient-derived metastatic CRC xenograft, with minimal gastrointestinal toxicity compared to other classes of WNT inhibitors. |